🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New subanalysis from MOMENTUM-3 on the impact of CIED, CRTD devices in HM3 LVADs now in Journal of Cardiac Failure onlinejcf.com/article/S1071-… No overall impact in survival, HFH or QOL metrics in those with devices vs. those without Gabriel Sayer Igor Gosev Hima Vidula, MD, MS, FACC

🚨New science alert! HM3 LVADs are associated w/hemodynamic related events like RVF. In this prospective RCT, pts who received a novel RV protection strategy upfront post-LVAD implant had better outcomes & less RVF. #THT2025 🔗: bit.ly/3CEDDN7

Fantastic talks by Samer Najjar and Richa Gupta on the AHF referral and evaluation process at our AHF symposium at #CRT2025 Farooq Sheikh Mark Hofmeyer MedStar Health Georgetown/WHC Cardiology Fellows

Great talk on HF epidemiology by Dr. Mandeep Mehra to open our HF symposium at #CRT2025! Farooq Sheikh Mark Hofmeyer MedStar Health Georgetown/WHC Cardiology Fellows Richa Gupta Miguel Pinilla-Vera

Outstanding talk on cardiac energetics by Jon Grinstein MD at #CRT2025! Looking forward to great things ahead! Farooq Sheikh Richa Gupta Mark Hofmeyer MedStar Health Georgetown/WHC Cardiology Fellows Miguel Pinilla-Vera

Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. A State-of-the-Art review published in #EHJ European Society of Cardiology European Society of Cardiology Journals #precisionmedicine #amyloidosis academic.oup.com/eurheartj/arti…

The Definition of Failure | New England Journal of Medicine nejm.org/doi/full/10.10… Food for thought from a New Zealand colleague Robert Mentz, MD Anu Lala-Trindade

#apixabaninHM3 With a dosing strategy to target trough apixaban levels of >50ng/ml, there were no major coagulopathic events in 34 HM3 patients during a follow-up of 3191 patient-days (820 patient-days in children). 🔗: jhltonline.org/article/S1053-…

Observational data on the rate of change at 1 year in CPET parameters in untreated and treated patients with transthyretin cardiac amyloidosis jacc.org/doi/epdf/10.10… #cardiotwitter

#JACCIMG state-of-the-art review: How has our understanding of cardiac #amyloidosis changed in the past decade? 🤔 Get the details here: jacc.org/doi/10.1016/j.… #cvImaging #CardioOnc #CardioX Sharmila Dorbala Michele Emdin Vasvi Singh

Welcome to the club Rory McIlroy. Completing the grand slam at Augusta is something special. Your determination during this round, and this entire journey has shown through, and now you’re a part of history. Proud of you!

👀Data on almost 1500 DCD 🫀transplants compared to DBD from The ISHLT registry by Rebecca Cogswell at #ISHLT2025. No difference in 1️⃣ year survival‼️ JHLT Jennifer Cowger

Congrats MWHC IM Residency Saad Mohammad and Georgetown/WHC Cardiology Fellows Marta Lorente Ros for this fantastic presentation at #ISHLT2025 on RVAD strategy and outcomes post-LVAD at our center! The future of cardiology is bright! MedStar Washington Farooq Sheikh Richa Gupta Ben Kenigsberg, MD

Father of contemporary preventive cardiology movement 🙌 Thanks for giving many of us the foundation to carry forward your message🙏

And we have the same #JCFFamily protocol at JCF Intersections! ✅ Rapid turnaround time ✅ Thoughtful assessment ✅ Open communication with authors ✅ No reformatting required Jason N. Katz Anthony Carnicelli, MD FACC Sarah Chuzi, MD, MSc Elliott Miller Shahzeb Khan Julie Doberne MD PhD Hawkins Gay, MD, MPH HFSA

🚨LATE-BREAKING DATA this weekend at #HeartFailure2025. Nir Uriel, MD MSc presented a comparative analysis on 2-year survival outcomes for #HeartMate3 LVAD and HTx patients <50 showing a 12% reduced mortality when measured from time of HM3 implant compared to death or delisting from

#JACCIMG explores the role of #whyCMR in lamin heart disease. CMR detects abnormal T2, ECV, & myocardial mechanics before any decline in systolic function. More LGE & worse mechanics appear to have prognostic potential. jacc.org/doi/10.1016/j.… #LMNA #DCM

How can the win ratio be effectively used and communicated in cardiovascular clinical trials? ahajournals.org/doi/full/10.11…